1. Home
  2. MRCY vs EWTX Comparison

MRCY vs EWTX Comparison

Compare MRCY & EWTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Mercury Systems Inc

MRCY

Mercury Systems Inc

SELL

Current Price

$78.01

Market Cap

5.0B

Sector

N/A

ML Signal

SELL

Logo Edgewise Therapeutics Inc.

EWTX

Edgewise Therapeutics Inc.

SELL

Current Price

$38.38

Market Cap

4.3B

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
MRCY
EWTX
Founded
1981
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.0B
4.3B
IPO Year
1997
2021

Fundamental Metrics

Financial Performance
Metric
MRCY
EWTX
Price
$78.01
$38.38
Analyst Decision
Buy
Buy
Analyst Count
11
13
Target Price
★ $114.80
$52.62
AVG Volume (30 Days)
568.9K
★ 1.5M
Earning Date
11-03-2026
11-05-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 23.08
N/A
EPS
★ N/A
N/A
Revenue
★ $983,622,000.00
N/A
Revenue This Year
$10.46
N/A
Revenue Next Year
$11.44
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
★ 7.85
N/A
52 Week Low
$65.04
$14.25
52 Week High
$128.45
$48.51

Technical Indicators

Market Signals
Indicator
MRCY
EWTX
Relative Strength Index (RSI) 35.02 36.31
Support Level $73.38 $37.75
Resistance Level $89.06 $41.22
Average True Range (ATR) 2.31 1.91
MACD 0.00 -0.27
Stochastic Oscillator 7.71 16.04

Price Performance

Historical Comparison
MRCY
EWTX

About MRCY Mercury Systems Inc

Mercury Systems Inc is a commercial technology company serving the aerospace and defense industry. The company envisions, creates, and delivers secure open architecture solutions powering a broad range of mission-critical applications in challenging and demanding environments. Its Mercury Processing Platform spans the full breadth of signal processing from radio frequency front end to the human-machine interface to convert meaningful data, gathered in remote and hostile environments, into critical decisions. The company manufactures components, products, modules, and subsystems and sells to defense prime contractors, the U.S. government, original equipment manufacturers, and commercial aerospace companies. Geographically, it derives maximum revenue from the United States.

About EWTX Edgewise Therapeutics Inc.

Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is developing novel therapeutics for muscular dystrophies and serious cardiac conditions. The company's product candidates are Sevasemten, EDG-7500, EDG-003, and EDG-15400. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies, including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company's products are currently in different stages of their development, being developed to target key muscle proteins and modulators to address a broad array of muscle diseases.

Share on Social Networks: